噻托溴铵联合舒利迭对哮喘-慢性阻塞性肺疾病重叠综合征患者肺功能的影响

Effect of Tiotropium Bromide Combined with Seretide on Lung Function in Patients with Asthma-chronic Obstructive Pulmonary Disease Overlap Syndrome

目的:探讨噻托溴铵联合舒利迭治疗哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)的临床效果和安全性。方法:选取2018年4月-2020年4月就诊于本院的86例ACOS患者,按随机数字表法分为观察组和对照组,每组43例。对照组予以舒利迭治疗,观察组加用噻托溴铵治疗。比较两组不良反应发生情况及治疗前后的肺功能指标[肺活量(FVC)、最大呼气中段流量(MMEF)、第1秒用力呼气容积(FEV1)和FEV1/FVC%]、睡眠状况[PSQI评分和每晚睡眠时间]。结果:治疗前,两组FVC、MMEF、FEV1、FEV1/FVC%比较,差异均无统计学意义(P>0.05);治疗后,观察组FVC、MMEF、FEV1、FEV1/FVC%为(3.16±0.42)L、(1.61±0.25)L/s、(2.41±0.39)L、(76.27±6.72)%均高于对照组的(2.93±0.38)L、(1.33±0.21)L/s、(2.04±0.32)L、(69.62±6.31)%,差异均有统计学意义(P<0.05)。治疗前,两组PSQI评分、睡眠时间比较,差异均无统计学意义(P>0.05);治疗后,观察组PSQI评分为(4.58±1.02)分低于对照组的(6.74±1.23)分,每晚睡眠时间为(7.48±1.21)h长于对照组的(6.69±1.17)h,差异均有统计学意义(P<0.05)。观察组不良反应发生率高于对照组,差异无统计学意义(P>0.05)。结论:噻托溴铵联合舒利迭治疗可改善ACOS患者肺功能,减轻病情程度,增强睡眠质量,安全可靠。

Objective:To investigate the clinical effect and safety of Tiotropium Bromide combined with Seretide in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).Method:A total of 86 cases with ACOS in our hospital from April 2018 to April 2020 were selected,and they were divided into observation group and control group according to the random number table method,43 cases in each group.The control group was treated with Seretide,and the observation group was treated with Tiotropium Bromide on the basis of control group.The occurrence of adverse reactions were compared between two groups,and lung function indexes[forced expiratory volume (FVC),maximum midexpiratory flow (MMEF),forced expiratory volume in the first second (FEV1) and FEV1/FVC%],sleep status[PSQI scores and sleep time per night]before and after treatment were compared between the two groups.Result:Before treatment,there were no significant differences in FVC,MMEF,FEV1,FEV1/FVC% between the two groups (P>0.05);after treatment,the FVC,MMEF,FEV1,FEV1/FVC% of the observation group were (3.16±0.42) L,(1.61±0.25) L/s,(2.41±0.39) L,(76.27±6.72) % were higher than those of the control group (2.93±0.38) L,(1.33±0.21) L/s,(2.04±0.32) L,(69.62±6.31) %,the differences were statistically significant (P<0.05).Before treatment,there were no significant differences in PSQI scores and sleep time per night between the two groups (P>0.05);after treatment,the PSQI score of the observation group was (4.58±1.02) points lower than (6.74±1.23) points of the control group,sleep time per night was (7.48±1.21) h longer than (6.69±1.17) h of the control group,and the differences were statistically significant (P<0.05).The incidence of adverse reactions of the observation group was higher than that of the control group,and the difference was not statistically significant (P>0.05).Conclusion:Tiotropium Bromide combined with Seretide can improve the lung function of patients with ACOS,reduce the severity of the disease,and enhance the quality of sleep,which is safe and reliable.